Public health guidance on active case finding of communicable diseases in prison settings
This joint guidance from ECDC and the European Monitoring Centre for Drugs and Drug Addiction provides EU/EEA Member States with evidence-based scientific advice on active case finding options. These options can be applied to the planning and implementation of interventions that promote the early diagnosis of communicable diseases in prison settings.
ECDC and EMCDDA make the case for active case finding of communicable diseases in prison
In their joint public health Guidance published today, ECDC and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), present the evidence on active case finding as a key measure to diagnose communicable diseases early.
Rapid risk assessment: Multi-country outbreak of hepatitis A virus genotype IA infections affecting EU countries in 2018
After the EPIS FWD notification of a cluster of hepatitis A cases infected with two distinct strains in several EU/EEA countries, this risk assessment presents the early findings of this multi-country hepatitis A outbreak and sets out initial options for response.
Molecular typing of Neisseria gonorrhoeae – a study of 2013 isolates
This report describes the second molecular typing survey of N. gonorrhoeae across the EU/EEA and provides recent information on NG-MAST STs/Gs and genotypes based on WGS circulating in 21 EU/EEA Member States.
Understanding drug-resistant gonorrhoea: an ECDC whole genome sequencing study
Can whole genome sequencing illustrate changes in drug susceptibility of gonorrhoea to antimicrobials used for treatment and so help to define more effective treatment regimens? The first study of this kind within an international surveillance programme for sexually transmitted infections shows distribution of drug-resistant gonorrhoea strains across Europe.
ECDC: first detected cases of extensively drug-resistant gonorrhoea threaten future treatment
Within a matter of weeks, three cases of gonorrhoea that are resistant to the recommended first line antibiotic treatment have been detected in Europe and Australia. These are the first global reports of Neisseria gonorrhoeae with high-level resistance to azithromycin and ceftriaxone resistance that also show resistance to several other vital antibiotics. At a time with limited alternatives to the current dual therapy, lack of a vaccine and insufficient surveillance capacity in some regions, these cases highlight the growing threat of drug-resistance – which could lead to untreatable gonorrhoea.
Rapid Risk Assessment: Extensively drug-resistant (XDR) Neisseria gonorrhoeae in the United Kingdom and Australia
This rapid risk assessment aims to assess the risk of XDR Neisseria gonorrhoeae spreading further in the EU/EEA and provide some options for response.
Communicable disease threats report, 29 April - 5 May 2018, Week 18
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 29 April - 5 May 2018 and includes updates on dengue, seasonal influenza, yellow fever, hepatitis A and polio.
Communicable disease threats report, 22-28 April 2018, week 17
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 22-28 April 2018 and includes updates on dengue, chikungunya, seasonal influenza, yellow fever, gonorrhoea and cholera.
Communicable disease threats report, 25-31 March 2018, week 13
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 25-31 March 2018 and includes updates on dengue, chikungunya, measles, listeria, Borna diseases and gonorrhoeae.